Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study
Study (n=299) of patients with stage IV melanoma on ipilimumab, nivolumab, or pembrolizumab (or combination) found that having ≥20% of infusions in the evening was associated with shorter overall survival vs in daytime (median 4.8 vs not reached; HR 2.04 [1.04 to 4.00; p=0.038]).
Source:
The Lancet Oncology
SPS commentary:
The authors note the dependence of the adaptive immune system on circadian rhythm is an emerging field of study with potential therapeutic implications, and that their results are in agreement with an increasing body of evidence that such responses are less robust when initially stimulated in the evening. Prospective studies in this area are required.